[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588943":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":24,"interventions":44,"overallOfficials":55,"centralContacts":60,"locations":66,"responsibleParty":83,"collaborators":13,"id":85,"slug":13,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":13,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":13,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":13,"overallStatus":69,"whyStopped":13,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 24","The EASI score is used to measure the severity and extent of AD and measured erythema, edema\u002Fpapulation, excoriation and lichenification on 4 anatomic regions of the body: head and neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.","Baseline, Week 24",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"TRIPLE",[21,22,23],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[25,30,35,38,41],{"label":26,"type":27,"description":13,"interventionNames":28},"Group 1","PLACEBO_COMPARATOR",[29],"Drug: Placebo Comparator",{"label":31,"type":32,"description":13,"interventionNames":33},"Group 2","EXPERIMENTAL",[34],"Biological: CM512",{"label":36,"type":32,"description":13,"interventionNames":37},"Group 3",[34],{"label":39,"type":32,"description":13,"interventionNames":40},"Group 4",[34],{"label":42,"type":27,"description":13,"interventionNames":43},"Group 5",[29],[45,50],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":13},"DRUG","Placebo Comparator","Placebo subcutaneous injection",[26,42],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":13},"BIOLOGICAL","CM512","CM512 subcutaneous injection",[31,36,39],[56],{"name":57,"affiliation":58,"role":59},"Jianzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":13,"email":65},"Qian Jia","CONTACT","+86-028-88610620","qianjia@keymedbio.com",[67],{"facility":68,"status":69,"city":70,"state":13,"zip":13,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Peking University People's hospital","RECRUITING","Beijing","China","CN",{"type":74,"coordinates":75},"Point",[76,77],116.39723,39.9075,{"lat":77,"lon":76},[80],{"name":57,"role":63,"phone":81,"phoneExt":13,"email":82},"15545433012","rmzjz@126.com",{"type":84,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100588943",false,"NCT06947980","Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria:\n* EASI≥16 at Screening and Baseline visits;\n* Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;\n\n  * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;\n* Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Concurrent disease\u002Fstatus which may potentially affect the efficacy\u002Fsafety judgement.\n* Organ dysfunction.\n* Pregnancy.\n* Other.","ALL","18 Years","75 Years",{"count":95,"type":96},200,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).",[102],"Atopic Dermatitis","2025-08-12",{"date":105,"type":106},"2025-08-17","ACTUAL",{"date":108,"type":106},"2025-06-19",{"date":110,"type":96},"2026-11-07",{"name":5,"class":6},1]